The Oncology Institute shares are trading lower after the company reported worse-than-expected Q2 financial results. Also the reiterated issued FY24 revenue guidance with its midpoint below estimates and cut its gross profit and adjusted EBITDA guidance.
Portfolio Pulse from Benzinga Newsdesk
The Oncology Institute shares are trading lower after reporting worse-than-expected Q2 financial results. The company also reiterated its FY24 revenue guidance with a midpoint below estimates and cut its gross profit and adjusted EBITDA guidance.
August 14, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The Oncology Institute shares are trading lower due to worse-than-expected Q2 financial results. The company also reiterated its FY24 revenue guidance with a midpoint below estimates and cut its gross profit and adjusted EBITDA guidance.
The disappointing Q2 financial results and the lowered FY24 guidance are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100